[Federal Register Volume 65, Number 161 (Friday, August 18, 2000)]
[Notices]
[Pages 50538-50539]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 00-21049]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Program Announcement 00132]


Cooperative Agreement to the Joint United Nations Programme on 
HIV/AIDS (UNAIDS); Notice of the Availability of Funds

A. Purpose

    The Centers for Disease Control and Prevention (CDC), National 
Center for HIV/STD/TB Prevention (NCHSTP), announces the availability 
of funds for fiscal year (FY) 2000 for a sole source cooperative 
agreement with the Joint United Nations Programme on HIV/AIDS (UNAIDS).
    The purpose of this agreement is to help support and ensure 
implementation of the Leadership and Investment in Fighting an Epidemic 
(LIFE) Initiative, a United States Government program that seeks to 
reduce the impact of HIV/AIDS in sub-Saharan African countries and 
India by strengthening the capacity of national AIDS control programs 
in the areas of (1) HIV primary prevention, (2) HIV care, support, and 
treatment, and (3) capacity and infrastructure development. At present, 
those countries are Botswana, Cote D'Ivoire, Kenya, South Africa, 
Uganda, Rwanda, Zimbabwe, Ethiopia, Mozambique, Malawi, Tanzania, 
Nigeria, Senegal, Zambia and India. The countries targeted represent 
those with the most severe epidemic and the highest number of new 
infections. They also represent countries where the potential for 
impact is greatest and where U.S. government agencies are already 
active.
    This agreement supports a framework of interventions, grounded in a 
series of goals and objectives consistent with those established for 
the international community by UNAIDS in support of the International 
Partnership Against AIDS in Africa (IPAA).
    According to recent estimates from UNAIDS and the World Health 
Organization (WHO), 32.4 million adults and 1.2 million children will 
be living with HIV by the end of 1999. Of the total estimate, 
approximately 23.3 million (69% of the total world-wide) adults and 
children are living with AIDS in sub-Saharan Africa alone. Of that 
total, approximately 3.8 million adults and children represent those 
newly infected with HIV in 1999. India carries the majority of the 
burden associated with an additional 1.3 million adults and children 
newly infected with HIV in 1999. As a key partner in the U.S. 
Government's LIFE Initiative, CDC, through its Global AIDS Activity 
(GAA), is working in a collaborative manner with national governments, 
USAID and other Federal agencies, and other international donor agency 
partners to develop programs of assistance to address the HIV/AIDS 
epidemic in LIFE Initiative countries.

B. Eligible Applicants

    Assistance will be provided only to the Joint United Nations 
Programme on HIV/AIDS (UNAIDS) in support of the LIFE Initiative. No 
other applications will be solicited.
    UNAIDS is the most appropriate and qualified agency to conduct the 
activities under this cooperative agreement because:
    1. As the Joint Programme for the entirety of the United Nations' 
efforts in the HIV/AIDS arena, UNAIDS is uniquely positioned to assist 
national AIDS control programs and other public health partners in 
development of capacity for HIV prevention and care.
    2. UNAIDS is spearheading the International Partnership Against 
HIV/AIDS (IPAA) in Africa, an international umbrella effort to increase 
support and visibility for a multi-lateral emergency response to the 
AIDS epidemic in Africa. The LIFE Initiative is a key supporter of the 
IPAA.
    3. The UNAIDS Secretariat currently administers a ``multi-bi'' 
instrument, the Programme Acceleration Fund (PAF), a mechanism for 
allocating resources through multiple UN Executing Agencies for 
multiple purposes in multiple countries, including those designated 
under the LIFE Initiative (UN Executing Agencies in countries are 
primarily the Cosponsoring Agencies of UNAIDS; World Health 
Organization (WHO), United Nations Children' Fund (UNICEF), United 
Nations Fund for Population Activities (UNFPA), United Nations 
Development Programme (UNDP), United Nations Education, Scientific and 
Cultural Organization (UNESCO), United Nations Drug Control Programme 
(UNDCP), and the World Bank.
    4. UNAIDS, has the primary responsibility to foster expanded 
national responses to the epidemic, to promote strong commitments by 
governments to an expanded response, to strengthen and coordinate the 
United Nation' action of HIV/AIDS at the global and national levels, 
and to identify, develop and advocate international best practice.

C. Availability of Funds

    Approximately $2,000,000 dollars is available in FY 2000 to fund 
this project. It is anticipated that the award will begin on September 
30, 2000, and will be made for a 12-month budget period within a 
project period of up to five years. Funding estimates may vary and are 
subject to change.
    Continuation awards within the project period will be made on the 
basis of satisfactory progress and availability of funds.

Use of Funds

General Use
    Funds may be used for strengthening the technical capacity of 
national AIDS control programs, the purchase of drugs for primary 
prevention (e.g., Sexually Transmitted Diseases (STD) and Tuberculosis 
(TB) treatment, prevention of perinatal HIV transmission, and other 
opportunistic infections related to AIDS illness) and for equipment, 
supplies and reagents for rapid screening for HIV and STDs, and in 
support of the delivery of HIV prevention and care and treatment 
services.
General Non-Use
    Funds received from this announcement will not be used for capital 
expenditures such as the purchase of off-road and multi-passenger 
vehicles, large volume (greater than 50) purchase of computers and data 
storage systems, space renovations and other significant improvements 
to physical environments where activities are carried out.
Specific Non-Use
    Funds received from this announcement will not be used for the 
direct purchase of antiretroviral drugs for treatment of established 
HIV infection, occupational exposures, and non-occupational exposures 
and will not be used for the direct purchase of equipment and reagents 
to conduct hospital-based laboratory monitoring for patient care or 
confirmatory tests.

D. Submission and Deadline

    Submit the original and two copies of PHS 5161 (OMB Number 0937-
0189). Forms are in the application kit.
    On or before September 15, 2000 submit the application to the 
Grants Management Specialist identified in the ``Where to Obtain 
Additional

[[Page 50539]]

Information'' section of this announcement.

E. Where To Obtain Additional Information

    This and other CDC announcements can be found on the CDC home page 
Internet address--http://www.cdc.gov. Scroll down the page, then click 
on ``Funding'' then ``Grants and Cooperative Agreements.''
    To receive additional written information and to request an 
application kit, call 1-888-GRANTS (1-888 472-6874). You will be asked 
to leave your name and address and will be instructed to identify the 
Announcement number of interest.
    If you have questions after reviewing the contents of all the 
documents, business management technical assistance may be obtained 
from: Roslyn Curington, Grants Management Specialist, Centers for 
Disease Control and Prevention (CDC), Procurement and Grants Office, 
Room 3000, 2920 Brandywine Road, Mailstop E-15, Atlanta, GA 30341-4146, 
Telephone: (770) 488-2767, E-mail: [email protected].
    For program technical assistance, contact: Leo Weakland, Deputy 
Coordinator, Global AIDS Activity (GAA), National Center for HIV, STD, 
and TB Prevention, Centers for Disease Control and Prevention (CDC), 
1600 Clifton Road, Mailstop E-07, Atlanta, GA 30333, Telephone number 
(404) 639-8016, Email address: [email protected].

    Dated: August 14, 2000.
John L. Williams,
Director, Procurement and Grants Office, Centers for Disease Control 
and Prevention.
[FR Doc. 00-21049 Filed 8-17-00; 8:45 am]
BILLING CODE 4163-18-P